Semaglutide (Ozempic) and tirzepatide (Mounjaro/Wegovy) are GLP-1 and GLP-1/GIP inhibitors respectively that suppress appetite and blood sugar; while beneficial for type 2 diabetics and morbidly obese individuals, they cause gastric emptying slowdown, paralytic gut, facial fat loss (Ozempic/Wegovy face), and cause approximately one-third to one-half of weight loss to be lean body mass rather than fat.
factualpending
Speaker
Gary BreckaEvidence Quote
“Semaglutide...Ozempic...tirzepatide...Mounjaro...are great for for people that have um that are type 2 diabetics or that are morbidly obese...what people are realizing now is all of the issues with gastric emptying, paralytic gut”
Created: 8/11/2026, 1:26:17 AM
Your notes
Loading notes...